3.83
-1.61(-29.60%)
Currency In USD
| Previous Close | 5.44 |
| Open | 5.11 |
| Day High | 5.2 |
| Day Low | 3.71 |
| 52-Week High | 135.54 |
| 52-Week Low | 3.06 |
| Volume | 1.89M |
| Average Volume | 1.39M |
| Market Cap | 3.07M |
| PE | 0 |
| EPS | -1,210.59 |
| Moving Average 50 Days | 6.31 |
| Moving Average 200 Days | 11.64 |
| Change | -1.61 |
If you invested $1000 in Alzamend Neuro, Inc. (ALZN) since IPO date, it would be worth $0.21 as of June 01, 2025 at a share price of $3.83. Whereas If you bought $1000 worth of Alzamend Neuro, Inc. (ALZN) shares 3 years ago, it would be worth $3.05 as of June 01, 2025 at a share price of $3.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
Massachusetts General Hospital Main Entrance Massachusetts General Hospital Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/br
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
GlobeNewswire Inc.
May 19, 2025 12:00 PM GMT
Massachusetts General Hospital Main Entrance Massachusetts General Hospital Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/br
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
GlobeNewswire Inc.
May 13, 2025 12:00 PM GMT
Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 13, 2025 (GLOB